Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:1375-1378
Published online before print May 1, 2008,
doi: 10.1161/ATVBAHA.108.166629
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:1375.)
© 2008 American Heart Association, Inc.
|
Cell Biology and Signaling |
Complete Downmodulation of P-Selectin Glycoprotein Ligand in Monocytes Undergoing Apoptosis
Jan-Julius Stampfuss;
Petra Censarek;
Jens W. Fischer;
Gernot Kaber;
Bernhard H. Rauch;
Kerstin Freidel;
Ute Fischer;
Klaus Schulze-Osthoff;
Tilo Grosser;
Maria Grandoch;
Karsten Schrör;
Artur-Aron Weber
From the Institut für Pharmakologie und Klinische Pharmakologie (J.-J.S., P.C., J.W.F., G.K., B.H.R., K.F., K.S.), Universitätsklinikum Düsseldorf, Germany; the Institut für Molekulare Medizin (U.T., K.S.-O.), Universitätsklinikum Düsseldorf, Germany; the Institute for Translational Medicine and Therapeutics (T.G.), University of Pennsylvania School of Medicine, Philadelphia; and the Institut für Pharmakologie (M.G., A.-A.W.), Universität Duisburg-Essen, Universitätsklinikum Essen, Germany.
Correspondence to Artur-Aron Weber, MD, Institut für Pharmakologie, Universität Duisburg-Essen, Universitätsklinikum Essen, Hufelandstr. 55, D-45122 Essen, Germany. E-mail artur.weber{at}uk-essen.de
 |
Abstract
|
|---|
Objectives— Apoptotic monocytes release membrane microparticles
which may play a major role in thrombogenicity through a P-selectin
glycoprotein ligand (PGSL-1)–mediated mechanism. We have
studied systematically the regulation of PSGL-1 expression and
function in apoptotic monocytic cells.
Methods and Results— PSGL-1 expression (flow cytometry, immunofluorescence microscopy, immunoblot) was virtually abolished in apoptotic monocytes by proteolytic shedding. This was accompanied by a complete loss of PSGL-1–mediated platelet–leukocyte (flow cytometry) and leukocyte–endothelial cell (parallel plate flow chamber) interactions. Systematic screening of protease inhibitors combined with knock-out and siRNA experiments characterized the PSGL-1-cleaving enzyme as an N-ethylmaleimide-inhibitable metalloproteinase of the ADAM family.
Conclusions— Downmodulation of PGSL-1 in apoptotic monocytes may prevent ectopic cell clearance in the peripheral vasculature to reduce local inflammatory and proliferative responses. Depletion of PSGL-1 expression on apoptotic microparticles may also act as a molecular switch to modulate their thrombogenic activity.
We have studied P-selectin glycoprotein ligand (PSGL-1) expression and function in apoptotic monocytic cells. PSGL-1 expression was virtually abolished by proteolytic ectodomain shedding resulting in a complete loss of platelet–leukocyte and leukocyte–endothelial cell interactions. Downmodulation of PGSL-1 may prevent ectopic cell clearance and may act as a molecular switch to reduce thrombogenicity.
Key Words: PSGL-1 apoptosis monocytes platelets endothelial cells
 |
Introduction
|
|---|
The cell adhesion molecules P-selectin glycoprotein ligand (PSGL-1)
and its receptor P-selectin (CD62P) are important mediators
in the primary interaction between leukocytes and both endothelial
cells and activated platelets.
1 PSGL-1–P-selectin interaction
has been also recognized as a crucial event in the incorporation
into growing thrombi of tissue factor-containing microparticles.
2 PSGL-1 expression was long considered unregulated. Evidence
has emerged, however, to link a reduction of cell surface PSGL-1
expression to stimulation of leukocytes.
3,4 An upregulation
of PSGL-1 on leukocytes from patients with chronic obstructive
pulmonary disease was also observed.
5 Recent data demonstrate
that PSGL-1 surface expression may be decreased in apoptotic
monocytic cells.
6 We have, therefore, studied systematically
the effects of apoptosis on PSGL-1 expression in function in
monocytes.
 |
Materials and Methods
|
|---|
Cell Systems and Transfection
U937 cells, human umbilical vein endothelial cells (HUVECs;
kindly provided by Dr U. Rauch, Charité, Berlin, Germany),
immortalized ADAM-10
–/– and -17
–/– MEFs
(kindly provided by Drs P. Saftig and S. Rose-John, University
of Kiel, Germany), and HEK293 cells were used. Human monocytes
and platelets were isolated from citrated blood. A human PSGL-1
cDNA clone was kindly provided by Dr D. Vestweber (University
of Münster, Germany). MEFs were transfected using Optifect
transfection reagent (Qiagen). For siRNA experiments, HEK293
cells were cotransfected with PSGL-1 cDNA and with ADAM-8 or
ADAM-9 siRNA using the DharmaFECT 1 siRNA Transfection Reagent.
Flow Cytometry
PSGL-1 expression was quantified using anti–PSGL-1–PE antibodies. Annexin-V–PE binding was measured using EDTA as a negative control. Monocyte-platelet aggregates were detected using anti–CD61-fluorescein isothiocyanate (FITC) antibodies and gating of monocytes on CD45-PE.
Immunofluorescence Microscopy, Immunoblotting, and Zymography
Methanol-fixed cells were stained with anti–PSGL-1 antibodies and Cy3-conjugated secondary antibodies. Protein expression was also determined by SDS-PAGE/Western blotting. Zymography was performed using SDS/polyacrylamide gels, containing gelatin.
Quantitative RT-PCR
qPCR was performed with TaqMan Universal PCR Master Mix (Applied Biosystems).
Perfusion Experiments
Parallel flow chamber perfusion experiments were performed at a shear rate of 125 s–1 using confluent HUVECs and calcein-AM-labeled U937 cells.
For details, see the supplemental materials (available online at http://atvb.ahajournals.org).
 |
Results
|
|---|
Staurosporine, dactinomycine, and etoposid led to an almost
complete downmodulation of PSGL-1 surface expression in U937
cells and in human blood monocytes, whereas cell activation
resulted in a modest reduction of PSGL-1 (
Figure 1A and 1B).
The kinetics of PSGL-1 reduction was nearly indentical with
the occurrence of apoptosis markers, (
Figure 2C through 2F)
and was prevented by VAD fmk, indicating an apoptosis-related
mechanism. Downmodulation of PSGL-1 was confirmed by Western
blotting and immunofluorescence microscopy (
Figure 1G and 1H).
A marked reduction of PSGL-1 mRNA was also observed. However,
because PSGL-1 was found to be a long-living protein, transcriptional
downregulation is unlikely to account for the complete loss
of the protein. Ultracentrifugation pellets and supernatants
of conditioned media were examined to discriminate soluble from
microparticle-bound PSGL-1 fragments. Staurosporine reduced
whereas PMA increased microparticle PSGL-1 expression, the latter
possibly reflecting the occurrence of a proteolytic fragment
(
Figure 2A and 2B). PE-conjugated anti–PSGL-1 antibodies
were released from the cell surface on apotosis induction (
Figure 2C),
indicating a proteolytical shedding. Systematic screening of
protease inhibitors combined with knock-out and siRNA experiments
characterized the PSGL-1-cleaving enzyme as an NEM-inhibitable
metalloproteinase of the ADAM family (
Figure 2E through 2G and
supplemental materials). Finally, both adhesion of activated
platelets to U937 cells and adhesion of U937 cells to HUVECs
were almost completely abolished by staurosporine treatment
(
Figure 2H and 2I).

View larger version (39K):
[in this window]
[in a new window]
|
Figure 1. Apoptosis-related downmodulation of PSGL-1 in U937 cells. Effects of staurosporine (A) as compared to PMA (B) on surface expression of PSGL-1. Time-course of staurosporine-induced PSGL-1 downmodulation (C) as compared to annexin-V binding (D), caspase-3 processing (E), and PARP cleavage (F). PSGL-1 downmodulation on treatment with staurosporine or PMA: (G) Western blot, (H) immunoflurescence microscopy.
|
|

View larger version (48K):
[in this window]
[in a new window]
|
Figure 2. Mechanisms and functional consequences of apoptosis-related shedding of PSGL-1 from U937 cells. A, Western blot analysis with conditioned media (medium), microparticle-free ultracentrifugation supernatants (SN), and microparticles (pellet) from control cells, PMA-, and staurosporine-treated cells. B, Effects of staurosporine as compared to PMA on microparticle PSGL-1 expression. C, Release of anti–PSGL-1–PE antibodies by staurosporine treatment. Effects of EDTA (D and E), phenanthroline, galardine (E), TAPI-0 (F), and NEM (G) on staurosporine-induced PSGL-1 shedding. H, Effects of staurosporine on platelet-monocyte aggregate formation (H) and monocyte adhesion to cultured endothelial cells (I).
|
|
For further details, see the supplemental materials.
 |
Discussion
|
|---|
We demonstrate that PSGL-1 is completely downmodulated in apoptotic
monocytes, unlike the partial reduction observed in response
to cell activation.
3 The mechanism underlying the depletion
of PSGL-1 on monocytic cells involved primarily proteolytic
shedding by an NEM–inhibitable metalloproteinase of the
ADAM family. Apoptosis-related PSGL-1 downmodulation resulted
in a complete loss of PSGL-1–dependent cell functions
(platelet–leukocyte and leukocyte–endothelial cell
interactions). These findings have several important physiological
and pathophysiological implications. Microparticle-associated,
blood-borne TF is incorporated into growing thrombi via PSGL-1
and contributes to thrombus propagation.
2 Thus, downmodulation
of this molecule during the apoptotic process may serve as a
protective molecular switch to alter this function of microparticles.
Phagocytosis of circulating apoptotic cells by the reticulo-endothelial
system occurs devoid of coincidental inflammation. One might
hypothesize that downmodulation of PSGL-1 in apoptotic monocytes
serves to prevent ectopic clearance of these cells in the peripheral
vasculature, thus preventing local inflammatory responses.
7 Similarly, the load of platelet-derived mitogenic and inflammatory
mediators
8 would be reduced markedly, when activated platelets
cannot adhere to PSGL-1–depleted apoptotic monocytes.
 |
Acknowledgments
|
|---|
The authors thank U. Rauch, S. Rose-John, P. Saftig, and D.
Vestweber for valuable reagents.
Sources of Funding
This work was supported by the Studienstiftung des Deutschen Volkes (to J.J.S.) and in part by the SFB612 (to J.W.F.).
Disclosures
None.
 |
Footnotes
|
|---|
Original received September 10, 2007; final version accepted
April 17, 2008.
 |
References
|
|---|
1. McEver RP, Cummings RD. Role of PSGL-1 binding to selectins in leukocyte recruitment.
J Clin Invest. 1997; 100: 97–103.
2. Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost. 2004; 92: 459–466.[Medline]
[Order article via Infotrieve]
3. Davenpeck KL, Brummet ME, Hudson SA, Mayer RJ, Bochner BS. Activation of human leukocytes reduces surface P-selectin glycoprotein ligand-1 (PSGL-1, CD162) and adhesion to P-selectin in vitro. J Immunol. 2000; 165: 2764–2772.[Abstract/Free Full Text]
4. Jilma B, Hergovich N, Homoncik M, Marsik C, Kreuzer C, Jilma-Stohlawetz P. Rapid down modulation of P-selectin glycoprotein ligand-1 (PSGL-1, CD162) by G-CSF in humans. Transfusion. 2002; 42: 328–333.[CrossRef][Medline]
[Order article via Infotrieve]
5. Schumacher A, Liebers U, John M, Gerl V, Meyer M, Witt C, Wolff G. P-selectin glycoprotein ligand-1 (PSGL-1) is up-regulated on leucocytes from patients with crhonic obstructive pulmonary disease. Clin Exp Immunol. 2005; 142: 370–376.[CrossRef][Medline]
[Order article via Infotrieve]
6. van Genderen H, Wielders SJ, Lindhout T, Reutelingsperger CP. Rolling and adhesion of apoptotic monocytes is impaired by loss of functional cell surface-expressed P-selectin glycoprotein ligand-1. J Thromb Haemost. 2006; 4: 1611–1617.[CrossRef][Medline]
[Order article via Infotrieve]
7. Fadeel B. Programmed cell clearance. Cell Mol Life Sci. 2003; 60: 2575–2585.[CrossRef][Medline]
[Order article via Infotrieve]
8. Weber A-A, Schrör K. The significance of platelet-derived growth factors for proliferation of vascular smooth muscle cells. Platelets. 1999; 10: 77–96.[CrossRef][Medline]
[Order article via Infotrieve]